Hiroshi MORIOKA

Prof. Hiroshi MORIOKA

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2019 in Molecules
Verified
Journal Article
Open access
PDF file
SYSoichiro Yamauchi
Soichiro Yamauchi
YKYoshihiro Kobashigawa
Yoshihiro Kobashigawa
NFNatsuki Fukuda
Natsuki Fukuda
MTManaka Teramoto
Manaka Teramoto
YTYuya Toyota
Yuya Toyota
HMHiroshi MORIOKA
Hiroshi MORIOKA
Single-chain Fv (scFv) antibodies are recombinant proteins in which the variable regions of the heavy chain (VH) and light chain (VL) are connected by a short flexible polypeptide linker. ScFvs have the advantages of easy genetic manipulation and low-cost production using Escherichia coli compared with monoclonal antibodies, and are thus expected to be utilized as next-generation medical antibodies. However, the practical use of scFvs has been limited due to low homogeneity caused by their aggregation propensity mediated by inter-chain VH-VL interactions. Because the interactions between the VH and VL domains of antibodies are generally weak, individual scFvs are assumed to be in equilibrium between a closed state and an open state, in which the VH and VL domains are assembled and disassembled, respectively. This dynamic feature of scFvs triggers the formation of dimer, trimer, and larger aggregates caused by the inter-chain VH-VL interactions. To overcome this problem, the N-terminus and C-terminus were herein connected by sortase A-mediated ligation to produce a cyclic scFv. Open-closed dynamics and aggregation were markedly suppressed in the cyclic scFv, as judged from dynamic light scattering and high-speed atomic force microscopy analyses. Surface plasmon resonance and differential scanning fluorometry analysis revealed that neither the affinity for antigen nor the thermal stability was disrupted by the scFv cyclization. Generality was confirmed by applying the present method to several scFv proteins. Based on these results, cyclic scFvs are expected to be widely utilized in industrial and therapeutic applications.

17 December 1998 in Biochemistry
Verified
Journal Article
Closed access
HKHiroyuki Kobayashi
Hiroyuki Kobayashi
HMHiroshi MORIOKA
Hiroshi MORIOKA
KTKunihiro Tobisawa
Kunihiro Tobisawa
TTTakuya Torizawa
Takuya Torizawa
Koichi KatoKoichi Kato
Koichi Kato
EOEiko Ohtsuka
Eiko Ohtsuka

1 January 2001 in Fusion Engineering and Design
Verified
Journal Article
Closed access
KNK. Nagasaki
K. Nagasaki
YIY. Itoh
Y. Itoh
KSK. Sakamoto
K. Sakamoto
TOT. Obiki
T. Obiki
TMT. Maekawa
T. Maekawa
HPH. Punzmann
H. Punzmann

9 August 2016 in The Journal of Biochemistry
Verified
Journal Article
Closed access
PDF file
NFNatsuki Fukuda
Natsuki Fukuda
YSYoshiaki Suwa
Yoshiaki Suwa
MUMakiyo Uchida
Makiyo Uchida
YKYoshihiro Kobashigawa
Yoshihiro Kobashigawa
HYHideshi Yokoyama
Hideshi Yokoyama
HMHiroshi MORIOKA
Hiroshi MORIOKA
Antibody is known to exhibit conformational change in the antigen recognition site after forming the initial complex. This structural change, which is widely known as “induced fit”, is believed to be critical for high affinity (Kd of nM range) of antigen-antibody interaction. Elucidation of this ‘induced fit’ process is essential for rational design of high affinity antibody, while it is prevented by limitation of the available biophysical and biochemical data of the initial complex. Here, we performed kinetic and thermodynamic analysis of the interaction between single-chain variable fragment (denoted as scFv) of 64M5 antibody and a (6-4) photoproduct by using surface plasmon resonance (denoted as SPR). It revealed that the 64M5scFv associates the (6-4) photoproduct at initial step by hydrophobic interactions, and enthalpy-driving interactions, hydrogen bonds and van der Waals interactions, were formed by second step structural rearrangement. Furthermore, mutational analysis revealed that the mobility of the antigen-binding site is critical for the second step. It could be assumed that optimization of the mobility of the antigen recognition site is a clue for rational design of high affinity antibody.

9 June 2023 in ACS Omega
Verified
Journal Article
Open access
KOKyo Okazaki
Kyo Okazaki
YKYoshihiro Kobashigawa
Yoshihiro Kobashigawa
HMHikari Morita
Hikari Morita
SYSoichiro Yamauchi
Soichiro Yamauchi
NFNatsuki Fukuda
Natsuki Fukuda
HMHiroshi MORIOKA
Hiroshi MORIOKA
Antibody drugs are denatured under physical stress, e.g., friction, heat, and freezing, which triggers formation of aggregates and resultant allergic reactions. Design of a stable antibody is thus critical for the development of antibody drugs. Here, we obtained a thermostable single-chain Fv (scFv) antibody clone by rigidifying the flexible region. We first conducted a short molecular dynamics (MD) simulation (3 runs of 50 ns) to search for weak spots in the scFv antibody, i.e., flexible regions located outside the CDR (complementarity determining region) and the interface between the heavy-chain and light-chain variable regions. We then designed a thermostable mutant and evaluated it by means of a short MD simulation (3 runs of 50 ns) based on reductions in the root-mean-square fluctuation (RMSF) values and formation of new hydrophilic interactions around the weak spot. Finally, we designed the VL-R66G mutant by applying our strategy to scFv derived from trastuzumab. Trastuzumab scFv variants were prepared by using an Escherichia coli expression system, and the melting temperaturemeasured as a thermostability indexwas 5 °C higher than that of the wild-type trastuzumab scFv, while the antigen-binding affinity was unchanged. Our strategy required few computational resources, and would be applicable to antibody drug discovery.

10 October 2017 in Molecules
Verified
Journal Article
Open access
PDF file
NFNatsuki Fukuda
Natsuki Fukuda
KNKentaro Noi
Kentaro Noi
LWLidong Weng
Lidong Weng
YKYoshihiro Kobashigawa
Yoshihiro Kobashigawa
HMHiromi Miyazaki
Hiromi Miyazaki
HMHiroshi MORIOKA
Hiroshi MORIOKA
Due to their lower production cost compared with monoclonal antibodies, single-chain variable fragments (scFvs) have potential for use in several applications, such as for diagnosis and treatment of a range of diseases, and as sensor elements. However, the usefulness of scFvs is limited by inhomogeneity through the formation of dimers, trimers, and larger oligomers. The scFv protein is assumed to be in equilibrium between the closed and open states formed by assembly or disassembly of VH and VL domains. Therefore, the production of an scFv with equilibrium biased to the closed state would be critical to overcome the problem in inhomogeneity of scFv for industrial or therapeutic applications. In this study, we obtained scFv clones stable against GA-pyridine, an advanced glycation end-product (AGE), by using a combination of a phage display system and random mutagenesis. Executing the bio-panning at 37 °C markedly improved the stability of scFvs. We further evaluated the radius of gyration by small-angle X-ray scattering (SAXS), obtained compact clones, and also visualized open